Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 19,676 |
|
|||||
| News | - | ||||||
| Day High | 16.50 | Low High |
|||||
| Day Low | 14.63 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Curis Inc | CRIS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.73 | -4.58% | 15.22 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.50 | 14.63 | 16.50 | 15.22 | 15.95 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 373 | 19,676 | $ 15.61 | $ 307,182 | - | 3.80 - 19.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:34:45 | 50 | $ 14.69 | USD |
Curis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 88.06M | 5.89M | - | 10.02M | -47.41M | -8.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Curis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRIS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.42 | 16.50 | 13.9914 | 15.47 | 20,644 | -0.20 | -1.30% |
| 1 Month | 10.26 | 17.49 | 10.02 | 14.68 | 42,250 | 4.96 | 48.34% |
| 3 Months | 9.26 | 17.49 | 8.24 | 11.82 | 35,021 | 5.96 | 64.36% |
| 6 Months | 5.04 | 17.49 | 3.80 | 10.19 | 63,969 | 10.18 | 201.98% |
| 1 Year | 19.80 | 19.80 | 3.80 | 13.65 | 177,129 | -4.58 | -23.13% |
| 3 Years | 224.00 | 348.00 | 3.80 | 88.88 | 1,410,306 | -208.78 | -93.21% |
| 5 Years | 36.40 | 348.00 | 3.80 | 96.82 | 1,573,242 | -21.18 | -58.19% |
Curis Description
| Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
